nach oben

Erschienen in:

22.03.2016 | Neuromyelitis-optica-Spektrum-Erkrankung | zertifizierte fortbildung

Neuroimmunologie

NMO-Spektrum-Erkrankungen

verfasst von: Steffen Pfeuffer, Univ-Prof. Dr. med. Heinz Wiendl

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

NMO-Spektrum-Erkrankungen sind eine Gruppe chronisch-entzündlicher ZNS-Erkrankungen, die vorrangig, aber nicht ausschließlich, durch rezidivierende Optikusneuritiden und/oder entzünd-liche Veränderungen des Rückenmarkes charakterisiert sind. Ausgehend von der Neuromyelitis optica wurden in den letzten Jahren wesentliche klinische, bildmorphologische und pathologische Erscheinungsformen charakterisiert, die nun unter dem Begriff der NMOSD firmieren. Im Juli 2015 wurden die bisherigen Diagnosekriterien revidiert und der vereinheitlichende Terminus „NMO-Spektrum-Erkrankung“ (NMOSD) eingeführt.

Jarius, S. and B. Wildemann, The history of neuromyelitis optica. Journal of neuroinflammation, 2013. 10: p. 8.PubMedPubMedCentralCrossRef

de Seze, J., et al., Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Multiple sclerosis, 2003. 9(5): p. 521–5.PubMedCrossRef

Wingerchuk, D.M., et al., The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology, 1999. 53(5): p. 1107–14.PubMedCrossRef

Lennon, V.A., et al., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, 2004. 364(9451): p. 2106–12.PubMedCrossRef

Lennon, V.A., et al., IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. The Journal of experimental medicine, 2005. 202(4): p. 473–7.PubMedPubMedCentralCrossRef

Wingerchuk, D.M., et al., Revised diagnostic criteria for neuromyelitis optica. Neurology, 2006. 66(10): p. 1485–9.PubMedCrossRef

Wingerchuk, D.M., et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015. 85(2): p. 177–89.PubMedPubMedCentralCrossRef

Jacob, A., et al., The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. Journal of neurology, 2013. 260(8): p. 2134–7.PubMedCrossRef

Asgari, N., et al., A population-based study of neuromyelitis optica in Caucasians. Neurology, 2011. 76(18): p. 1589–95.PubMedPubMedCentralCrossRef

10.

Bizzoco, E., et al., Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. Journal of neurology, 2009. 256(11): p. 1891–8.PubMedCrossRef

11.

Kira, J., et al., Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Annals of neurology, 1996. 40(4): p. 569–74.PubMedCrossRef

12.

Kira, J., Multiple sclerosis in the Japanese population. The Lancet. Neurology, 2003. 2(2): p. 117–27.PubMed

13.

Tanaka, K., et al., Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Multiple sclerosis, 2007. 13(7): p. 850–5.PubMedCrossRef

14.

Tanaka, M., et al., Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. Journal of neurology, neurosurgery, and psychiatry, 2007. 78(9): p. 990–2.PubMedPubMedCentralCrossRef

15.

Pittock, S.J., et al., Brain abnormalities in neuromyelitis optica. Archives of neurology, 2006. 63(3): p. 390–6.PubMedCrossRef

16.

Jarius, S., et al., Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of neuroinflammation, 2012. 9: p. 14.PubMedPubMedCentralCrossRef

17.

Quek, A.M., et al., Effects of age and sex on aquaporin-4 autoimmunity. Archives of neurology, 2012. 69(8): p. 1039–43.PubMedPubMedCentralCrossRef

18.

McKeon, A., et al., Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle & nerve, 2009. 39(1): p. 87–90.CrossRef

19.

Vaknin-Dembinsky, A., et al., Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Archives of neurology, 2011. 68(12): p. 1557–61.PubMedCrossRef

20.

Spillane, J., et al., Myasthenia gravis and neuromyelitis opica: A causal link. Multiple sclerosis and related disorders, 2013. 2(3): p. 233–7.PubMedCrossRef

21.

Nagaishi, A., et al., Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. Journal of neurology, neurosurgery, and psychiatry, 2011. 82(12): p. 1360–4.PubMedCrossRef

22.

Bergamaschi, R., et al., Two cases of benign neuromyelitis optica in patients with celiac disease. Journal of neurology, 2009. 256(12): p. 2097–9.PubMedCrossRef

23.

Jarius, S., et al., Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. Journal of neurology, neurosurgery, and psychiatry, 2008. 79(9): p. 1084.PubMedCrossRef

24.

Wingerchuk, D.M. and B.G. Weinshenker, The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple sclerosis, 2012. 18(1): p. 5–10.PubMedCrossRef

25.

Pittock, S.J., et al., Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Archives of neurology, 2006. 63(7): p. 964–8.PubMedCrossRef

26.

Saadoun, S., et al., Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain: a journal of neurology, 2010. 133(Pt 2): p. 349–61.CrossRef

27.

Hinson, S.R., et al., Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. The Journal of experimental medicine, 2008. 205(11): p. 2473–81.PubMedPubMedCentralCrossRef

28.

Zamvil, S.S. and A.J. Slavin, Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurology(R) neuroimmunology & neuroinflammation, 2015. 2(1): p. e62.CrossRef

29.

Roemer, S.F., et al., Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain: a journal of neurology, 2007. 130(Pt 5): p. 1194–205.CrossRef

30.

Jarius, S., et al., Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. Journal of the neurological sciences, 2011. 306(1-2): p. 82–90.PubMedCrossRef

31.

Uzawa, A., et al., Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple sclerosis, 2010. 16(12): p. 1443–52.PubMedCrossRef

32.

Linhares, U.C., et al., The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. Journal of clinical immunology, 2013. 33(1): p. 179–89.PubMedCrossRef

33.

Schneider-Hohendorf, T., et al., VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. The Journal of experimental medicine, 2014. 211(9): p. 1833–46.PubMedPubMedCentralCrossRef

34.

Barnett, M.H., et al., Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Multiple sclerosis, 2012. 18(1): p. 108–12.PubMedCrossRef

35.

Kim, H.J., et al., MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology, 2015. 84(11): p. 1165–73.PubMedPubMedCentralCrossRef

36.

Matiello, M., et al., NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology, 2008. 70(23): p. 2197–200.PubMedCrossRef

37.

Nakajima, H., et al., Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC neurology, 2010. 10: p. 45.PubMedPubMedCentralCrossRef

38.

Trebst, C., et al., Longitudinal extensive transverse myelitis—it’s not all neuromyelitis optica. Nature reviews. Neurology, 2011. 7(12): p. 688–98.PubMed

39.

Jiao, Y., et al., Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA neurology, 2014. 71(1): p. 48–54.PubMedPubMedCentralCrossRef

40.

Flanagan, E.P., et al., Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA neurology, 2015. 72(1): p. 81–7.PubMedPubMedCentralCrossRef

41.

Kim, S.H., et al., A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLoS One, 2014. 9(9): p. e108320.PubMedPubMedCentralCrossRef

42.

Weinshenker, B.G., et al., Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of neurology, 2006. 59(3): p. 566–9.PubMedCrossRef

43.

Popescu, B.F., et al., Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology, 2011. 76(14): p. 1229–37.PubMedPubMedCentralCrossRef

44.

Takahashi, T., et al., Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. Journal of neurology, neurosurgery, and psychiatry, 2008. 79(9): p. 1075–8.PubMedCrossRef

45.

Chan, K.H., et al., Brain involvement in neuromyelitis optica spectrum disorders. Archives of neurology, 2011. 68(11): p. 1432–9.PubMedCrossRef

46.

Kume, K., et al., Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. Multiple sclerosis, 2015. 21(7): p. 960–2.PubMedCrossRef

47.

Poppe, A.Y., et al., Neuromyelitis optica with hypothalamic involvement. Multiple sclerosis, 2005. 11(5): p. 617–21.PubMedCrossRef

48.

Matthews, L., et al., Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology, 2013. 80(14): p. 1330–7.PubMedPubMedCentralCrossRef

49.

Wingerchuk, D.M., et al., A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology, 2007. 68(8): p. 603–5.PubMedCrossRef

50.

Jarius, S., et al., Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nature clinical practice. Neurology, 2008. 4(4): p. 202–14.PubMed

51.

Jeffery, A.R. and J.R. Buncic, Pediatric Devic’s neuromyelitis optica. Journal of pediatric ophthalmology and strabismus, 1996. 33(5): p. 223–9.PubMed

52.

Wingerchuk, D.M. and B.G. Weinshenker, Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology, 2003. 60(5): p. 848–53.PubMedCrossRef

53.

Lukas, C., et al., Muensteraner MRT-Basisprotokoll. 2011.

54.

Jarius, S., et al., Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. Journal of neurology, neurosurgery, and psychiatry, 2008. 79(10): p. 1134–6.PubMedCrossRef

55.

Pittock, S.J., et al., Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA neurology, 2014. 71(11): p. 1433–6.PubMedCrossRef

56.

Waters, P.J., et al., Evaluation of aquaporin-4 antibody assays. Clinical and Experimental Neuroimmunology, 2014. 5(3): p. 290–303.CrossRef

57.

Jurynczyk, M., et al., Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of neurology, 2015.

58.

Jarius, S. and B. Wildemann, AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nature reviews. Neurology, 2010. 6(7): p. 383–92.PubMed

59.

Takahashi, T., et al., Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain: a journal of neurology, 2007. 130(Pt 5): p. 1235–43.CrossRef

60.

Jarius, S., et al., Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain: a journal of neurology, 2008. 131(Pt 11): p. 3072–80.CrossRef

61.

Jiao, Y., et al., Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology, 2013. 81(14): p. 1197–204.PubMedPubMedCentralCrossRef

62.

Probstel, A.K., et al., Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. Journal of neuroinflammation, 2015. 12: p. 46.PubMedPubMedCentralCrossRef

63.

O’Connor, K.C., et al., Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature medicine, 2007. 13(2): p. 211–7.PubMedPubMedCentralCrossRef

64.

Kim, S.M., et al., Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology(R) neuroimmunology & neuroinflammation, 2015. 2(6): p. e163.CrossRef

65.

Kitley, J., et al., Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology, 2012. 79(12): p. 1273–7.PubMedCrossRef

66.

Cobo-Calvo, A., et al., Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Multiple sclerosis, 2015.

67.

Sato, D.K., et al., Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology, 2014. 82(6): p. 474–81.PubMedPubMedCentralCrossRef

68.

Takano, R., et al., Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology, 2010. 75(3): p. 208–16.PubMedCrossRef

69.

Pittock, S.J., et al., Neuromyelitis optica and non organ-specific autoimmunity. Archives of neurology, 2008. 65(1): p. 78–83.PubMedCrossRef

70.

Wingerchuk, D.M. and B.G. Weinshenker, Neuromyelitis optica. Current treatment options in neurology, 2008. 10(1): p. 55–66.PubMedCrossRef

71.

Kleiter, I., et al., Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses. Annals of neurology, 2015.

72.

Watanabe, S., et al., Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Multiple sclerosis, 2007. 13(1): p. 128–32.PubMedCrossRef

73.

Abboud, H., et al., Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Multiple sclerosis, 2015.

74.

Bonnan, M., et al., Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Multiple sclerosis, 2009. 15(4): p. 487–92.PubMedCrossRef

75.

Absoud, M., et al., Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). BMJ open, 2015. 5(5): p. e008312.PubMedPubMedCentralCrossRef

76.

Elsone, L., et al., Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Multiple sclerosis, 2014. 20(4): p. 501–4.PubMedCrossRef

77.

Viswanathan, S., et al., Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. Journal of neuroimmunology, 2015. 282: p. 92–6.PubMedCrossRef

78.

Papeix, C., et al., Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Multiple sclerosis, 2007. 13(2): p. 256–9.PubMedCrossRef

79.

Shimizu, Y., et al., Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. Journal of neurology, 2008. 255(2): p. 305–7.PubMedCrossRef

80.

Min, J.H., B.J. Kim, and K.H. Lee, Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Multiple sclerosis, 2012. 18(1): p. 113–5.PubMedCrossRef

81.

Kleiter, I., et al., Failure of natalizumab to prevent relapses in neuromyelitis optica. Archives of neurology, 2012. 695(2): p. 239–45.CrossRef

82.

Azzopardi, L., et al., Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. Journal of neurology, 2015.

83.

Trebst, C., et al., Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of neurology, 2014. 261(1): p. 1–16.PubMedPubMedCentralCrossRef

84.

Elsone, L., et al., Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Multiple sclerosis, 2014. 20(11): p. 1533–40.PubMedCrossRef

85.

Costanzi, C., et al., Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology, 2011. 77(7): p. 659–66.PubMedCrossRef

86.

Mandler, R.N., W. Ahmed, and J.E. Dencoff, Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology, 1998. 51(4): p. 1219–20.PubMedCrossRef

87.

Jacob, A., et al., Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Archives of neurology, 2009. 66(9): p. 1128–33.PubMedCrossRef

88.

Huh, S.Y., et al., Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA neurology, 2014. 71(11): p. 1372–8.PubMedCrossRef

89.

Mealy, M.A., et al., Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA neurology, 2014. 71(3): p. 324–30.PubMedCrossRef

90.

van Meerten, T., et al., Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical cancer research: an official journal of the American Association for Cancer Research, 2006. 12(13): p. 4027–35.CrossRef

91.

Shan, D., J.A. Ledbetter, and O.W. Press, Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer immunology, immunotherapy: CII, 2000. 48(12): p. 673–83.PubMedCrossRef

92.

Castillo-Trivino, T., et al., Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One, 2013. 8(7): p. e66308.PubMedPubMedCentralCrossRef

93.

Kim, S.H., et al., Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. JAMA neurology, 2015. 72(9): p. 989–95.PubMedCrossRef

94.

Pellkofer, H.L., et al., Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology, 2011. 76(15): p. 1310–5.PubMedCrossRef

95.

Bedi, G.S., et al., Impact of rituximab on relapse rate and disability in neuromyelitis optica. Multiple sclerosis, 2011. 17(10): p. 1225–30.PubMedCrossRef

96.

Kim, S.H., et al., A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA neurology, 2013. 70(9): p. 1110–7.PubMedCrossRef

97.

Cree, B.A., et al., An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005. 64(7): p. 1270–2.PubMedCrossRef

98.

Kim, S.H., et al., Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Archives of neurology, 2011. 68(11): p. 1412–20.PubMedCrossRef

99.

Araki, M., et al., Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Modern rheumatology / the Japan Rheumatism Association, 2013. 23(4): p. 827–31.PubMedPubMedCentralCrossRef

100.

Ayzenberg, I., et al., Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA neurology, 2013. 70(3): p. 394–7.PubMedCrossRef

101.

Ringelstein, M., et al., Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA neurology, 2015. 72(7): p. 756–63.PubMedCrossRef

102.

Pittock, S.J., et al., Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. The Lancet. Neurology, 2013. 12(6): p. 554–62.PubMed

103.

Kleiter, I. and R. Gold, Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 2015.

Titel: Neuroimmunologie
NMO-Spektrum-Erkrankungen
verfasst von: Steffen Pfeuffer
Univ-Prof. Dr. med. Heinz Wiendl
Publikationsdatum: 22.03.2016
Verlag: Springer Medizin
Schlagwörter: Neuromyelitis-optica-Spektrum-Erkrankung
Optikusneuritis
Multiple Sklerose
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 3/2016
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-016-1586-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Spezifisches Antidot für den Notfall

Stringent an Skalen orientierte Behandlung ist der Standardtherapie überlegen

Multiple Sklerose und Salz

Balance zwischen Wirksamkeit und Therapiebelastung

Broschüre zu nächtlichen Wadenkrämpfen

Ginkgo-Extrakt als Therapieoption in die Leitlinie aufgenommen